clinic characteristics; program reach; CRC screening practices and outcomes; clinics' quality improvement and monitoring activities; EBI implementation, and additional factors that affect EBI implementation over time. The Quarterly Program Update is administered in the month following each program quarter (*i.e.*, October, January, April, July) and collects standardized recipient-level information on aspects of program management, including: quarterly program expenditures, current staff vacancies, program successes and challenges, current TA needs, and the effect of COVID–19 on CRCCP implementation at the recipient level. These data are collected quarterly to facilitate rapid reporting of programmatic information to support CDC program consultants in providing tailored and meaningful TA. This information collection enables

CDC to gauge progress in meeting

# ESTIMATED ANNUALIZED BURDEN HOURS

CRCCP program goals and monitor implementation activities, evaluate outcomes, and identify recipients' TA needs. In addition, data collected will inform program improvement and help identify successful activities that need to be maintained, replicated, or expanded. OMB approval is requested for three years. The total estimated annualized burden is 760 hours. There is no cost to respondents other than their time to participate.

Type of respondent	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hr)
CRCCP Recipients	CRCCP Annual Awardee Survey CRCCP Clinic-level Information Collection In- strument.	35 35	1 24	15/60 50/60
	CRCCP Quarterly Program Update	35	4	22/60

#### Jeffrey M. Zirger,

Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention.

[FR Doc. 2024–09145 Filed 4–26–24; 8:45 am] BILLING CODE 4163–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

## Meeting of the Healthcare Infection Control Practices Advisory Committee

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

# ACTION: Notice of meeting.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention announces the following meeting for the Healthcare Infection Control Practices Advisory Committee (HICPAC). This virtual meeting is open to the public, limited only by the number of audio and web conference lines (500 audio and web conference lines are available). Time will be available for public comment. Registration is required.

**DATES:** The meeting will be held on June 6, 2024, from 9 a.m. to 5 p.m., EDT, and June 7, 2024, 9 a.m. to 12 p.m., EDT.

**ADDRESSES:** To register for this web conference, please go to: *www.cdc.gov/ hicpac.* All registered participants will receive the meeting link and instructions shortly before the meeting. Please click the link below to join the June 6 webinar: https:// cdc.zoomgov.com/j/1619798307? pwd=cmdUT3IFNHFCN itXZElUdkdnZDRmQT09.

Passcode: fHTc=?7n. Please click the link below to join the June 7 Webinar: https:// cdc.zoomgov.com/j/1615598629? pwd=Ny9pcjhROGR2dGZNeUlmaTQv QWZxZz09.

Passcode: 8rLxq?\*f.

FOR FURTHER INFORMATION CONTACT: Sydnee Byrd, M.P.A., HICPAC, Division of Healthcare Quality Promotion, NCEZID, CDC, 1600 Clifton Road NE, Mailstop H16–3, Atlanta, Georgia 30329–4027, Telephone: (404) 718– 8039; Email: *hicpac@cdc.gov.* 

# SUPPLEMENTARY INFORMATION:

Purpose: The Committee is charged with providing advice and guidance to the Director, Division of Healthcare Quality Promotion (DHQP), the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), the Director, CDC, and the Secretary, Department of Health and Human Services, regarding (1) the practice of healthcare infection prevention and control; (2) strategies for surveillance, prevention, and control of infections, antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of CDC guidelines and other policy statements regarding prevention of healthcare-associated infections and healthcare-related conditions.

*Matters to be Considered:* The agenda will include the following updates: The Healthcare Personnel Guideline Workgroup; Isolation Precautions Guideline Workgroup; NHSN workgroup; and Dental Unit Waterlines Guideline Update. Agenda items are subject to change.

## **Public Participation**

Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below: All persons interested in making an oral public comment at the June 6-7, 2024 HICPAC meeting must submit a request between May 13, 2024, and May 24, 2024, at https://www.cdc.gov/hicpac/ meeting.html no later than 11:59 p.m., EDT, May 22, 2024, according to the instructions provided on the HICPAC website. If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery draw to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email on May 27, 2024.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2024–09090 Filed 4–26–24; 8:45 am] BILLING CODE 4163–18–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Centers for Disease Control and Prevention

[Docket No. CDC-2024-0034]

### Meeting of the Advisory Committee to the Director (ACD), Centers for Disease Control and Prevention

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). **ACTION:** Notice of meeting and request for comment.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting for the Advisory Committee to the Director, Centers for Disease Control and Prevention (ACD, CDC). This meeting is open to the public. The meeting will be webcast live via the World Wide Web.

**DATES:** The meeting will be held on June 6, 2024, from 10 a.m. to 3 p.m., EDT (times subject to change).

The public may submit written comments from April 29, 2024 through May 24, 2024.

**ADDRESSES:** No registration is required to view the meeting via the World Wide Web. Information for accessing the webcast will be available at *https:// www.cdc.gov/about/advisorycommittee-director/*.

*Written comments:* You may submit comments identified by Docket No. CDC–2024–0034 by either of the following methods below. Do not submit comments for the docket by email. CDC does not accept comments for the docket by email.

• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments.

• *Mail:* Tiffany Brown, JD MPH, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H21–10, Atlanta, Georgia 30329–4027. Attn: Docket number CDC– 2024–0034.

*Instructions:* All submissions received must include the Agency name and

Docket Number. All relevant comments received in conformance with the *https://www.regulations.gov,* suitability policy will be posted without change to *https://www.regulations.gov,* including any personal information provided. For access to the docket to read background documents or comments received, go to *https://www.regulations.gov.* Written public comments submitted up to 72 hours prior to the ACD meeting will be provided to ACD members before the meeting. Written comments received in advance of the meeting will be included in the official record of the meeting.

## FOR FURTHER INFORMATION CONTACT:

Tiffany Brown, JD MPH, Centers for Disease Control and Prevention, Office of the Chief of Staff, 1600 Clifton Road NE, Mailstop H21–10, Atlanta, Georgia 30329–4027, Telephone: (404) 498– 6655; Email Address: *ACDirector@ cdc.gov.* 

#### SUPPLEMENTARY INFORMATION:

Purpose: The Advisory Committee to the Director, CDC, shall (1) make recommendations to the Director regarding ways to prioritize the activities of the agency in alignment with the CDC Strategic Plan required under section 305(c); H.R. 2617–1252; (2) advise on ways to achieve or improve performance metrics in relation to the CDC Strategic Plan, and other relevant metrics, as appropriate; (3) provide advice and recommendations on the development of the Strategic Plan, and any subsequent updates, as appropriate; (4) advise on grant, cooperative agreements, contracts, or other transactions, as applicable; (5) provide other advice to the Director, as requested, to fulfill duties under sections 301 and 311; and (6) appoint subcommittees. The committee recommends ways to prioritize CDC's activities, improve results, and address health disparities. It also provides guidance to help CDC work more effectively with its various private and public sector constituents to make health protection a practical reality.

Matters to be Considered: The agenda will include an update on CDC priorities from the CDC Director, discussions on CDC's work to address equity and social determinants of health, lab readiness and response improvement efforts, programmatic updates, and updates from the ACD Data and Surveillance Workgroup and the Communications and Public Engagement Workgroup. Agenda items are subject to change as priorities dictate.

#### **Public Participation**

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on *https://www.regulations.gov*. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/ near duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket.

*Written Public Comment:* The docket will be opened to receive written comments on April 29, 2024 through May 24, 2024.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

# Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2024–09081 Filed 4–26–24; 8:45 am] BILLING CODE 4163–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Centers for Medicare & Medicaid Services

[CMS-3462-PN]

### Medicare Program; Application by The Compliance Team (TCT) for Continued CMS Approval of its Home Infusion Therapy (HIT) Accreditation Program

**AGENCY:** Centers for Medicare & Medicaid Services (CMS), HHS. **ACTION:** Notice with request for comment.